

№472, 31-yanvar, 2022 y.

COVID-19 ga qarshi vaksinalarning
ishlanmalari bo'yicha

DAYJEST

O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi
Ilmiy-texnik axborot markazi











Toshkent-2022

Jahonda pandemiya bilan bog'liq vaziyat

2022 y. 30-yanvar holatiga ko'ra

Umumiy zararlanganlar soni	-	372 931 512	(+ 2 658 162)
Sog'ayganlar soni	-	294 515 650	(+ 2 143 122)
Vafot etganlar soni	-	5 675 429	(+ 7 687)

Mamlakatlar bo'yicha bemorlar soni

	AQSh	-	75 481 122	(+ 192 028)
	Hindiston	-	41 092 522	(+ 234 281)
	Braziliya	-	25 247 477	(+ 207 316)
	Buyuk Britaniya	-	18 808 625	(+ 332 398)
	Fransiya	-	16 406 123	(+ 72 727)
	Rossiya	-	11 615 779	(+ 113 122)
	Turkiya	-	11 438 476	(+ 94 783)
	Italiya	-	10 821 420	(+ 137 192)
	Ispaniya	-	9 779 130	(+ 133 553)
	O'zbekiston	-	223 008	(+ 1 086)

Manba: <https://www.worldometers.info/coronavirus/>



O'zbekistonda COVID-19 qarshi vaksinatsiya bo'yicha hisobot

2022 y. 29-yanvar holatiga ko'ra

Hududlar	Jami emlanganlar soni	Bir kunda emlanganlar soni
Qoraqalpog'iston Respublikasi	2 116 356	1 852
Andijon viloyati	4 003 537	13 536
Buxoro viloyati	2 333 304	4 206
Jizzax viloyati	1 451 872	2 246
Qashqadaryo viloyati	3 226 349	10 902
Navoiy viloyati	1 337 909	1 984
Namangan viloyati	3 889 418	6 496
Samarqand viloyati	5 104 095	10 370
Surxondaryo viloyati	3 328 946	6 807
Sirdaryo viloyati	903 384	1 059
Toshkent viloyati	3 960 361	9 032
Farg'ona viloyati	4 560 496	9 926
Xorazm viloyati	2 516 399	3 307
Toshkent sh.	3 266 470	14 790
Jami	41 998 896	96 513

Manba: SSV matbuot kotibi // <https://t.me/ssvmatbuotkotibi>



JSST tomonidan baholash jarayonida COVID-19 ga qarshi vaksinlarning holati

2022 y. 28-yanvar holatiga ko'ra


№	Ishlab chiqaruvchi	Vaksina nomi	Platforma	Arizalarni qabul qilish	Uchrashuv o'tkazish	Ma'lumotnomani ko'rib chiqish uchun qabul qilish	Baholash holati	Kutilayotgan chiqish sanasi
1	Pfizer	BNT162b2/COMIRNATY	mRNA	+	+	+	Yakunlangan	Tasdiqlangan 31.12.2020
2	AstraZeneca/University of Oxford	AZD1222	Recombinant replication defective chimpanzee adenovirus expressing surface glycoprotein SARS-CoV-2	+	+	+	Yakunlangan	Tasdiqlangan 15.02.2021
3	Janssen	Ad26.COV2.S	Recombinant vector vaccine against adenovirus type 26 (Ad26), incapable of replication, encoding Spike (S) protein (SARS-CoV-2)	+	+	+	Yakunlangan	Tasdiqlangan 12.03.2021
4	SK BIOscience - AstraZeneca/University of Oxford	AZD1222	Recombinant adenoviral vector ChAdOx1 encoding the Spike SARS-CoV-2 protein antigen	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
5	Serum institute of India	Covishield	mRNA-based vaccine encapsulated in lipid nanoparticles	+	+	+	Yakunlangan	Tasdiqlangan 30.04.2021
6	Moderna	mRNA-1273	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 07.05.2021
7	Sinopharm / BIBP	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 01.06.2021
8	Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Protein subunit virus-like particle vaccine	+	+	+	Yakunlangan	Tasdiqlangan 17.12.2021
9	Novavax	NVX-CoV2373, Covovax, Nuvaxovid						

Manba:

Status of COVID-19 Vaccines within WHO EUL // https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Oct2021.pdf

Vaksinani tasdiqlagan va undan foydalanilayotgan mamlakatlar soni

2022 y. 28-yanvar holatiga ko'ra



Manbalar:

*Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

COVID-19 Vaccine Market Dashboard //

<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>


**Tracking Coronavirus Vaccinations Around the World //

<https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>

Mamlakatlar va kontinentlar kesimida COVID-19 ga qarshi emlanganlar soni

2022 y. 28-yanvar holatiga ko'ra

№	Davlatlar	Emlanganlar soni		Aholining umumiy sonida emlanganlarning ulushi	
		100 ta kishiga	Jami	Bitta doza bilan emlangan	To'liq emlangan
	Dunyo	131	10 034 508 831	63%	53%
1	BAA	240	23 452 398	>99%	95%
2	Bruney	223	965 131	94%	93%
3	Portugaliya	208	21 328 025	93%	90%
4	Kuba	300	33 968 091	93%	87%
5	Chili	245	46 450 064	93%	89%
6	Malta	240	1 206 841	92%	89%
7	Xitoy	214	2 989 480 000	91%	88%
8	Argentina	193	86 525 418	88%	77%
9	Kambodja	200	33 050 752	87%	83%
10	Ispaniya	191	89 717 860	87%	81%




Manba:
Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



COVID-19 ga qarshi vaksinalarning narxi

2022 y. 28-yanvar holatiga ko'ra

No	Vaksinaning ishlab chiqaruvchisi	Vaksinalarning narxi (bitta doza uchun)*
1	Pfizer	\$6,75-22,94
2	AstraZeneca/University of Oxford	\$2,19-5
3	Serum institute of India	\$3-13,27
4	Sinopharm	\$144,27 (2 ta doza uchun)
5	Sinovac	\$10,30-29,75
6	Moderna	\$15-37
7	Janssen	\$8,50-10
8	The Gamaleya National Center (Sputnik V)	\$11-19,90



Manba:

* COVID-19 Vaccine Market Dashboard //

[https://www.unicef.org/supply/covid-19-vaccine-market-](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)

[dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)



Vaksinaning uchinchi dozasi koronavirusning “Delta” va “Omikron” shtammlariga qarshi immunitetni sezilarli darajada kuchaytirishi mumkin

AQSH Kasalliklarni nazorat qilish va oldini olish markazlari (CDC) Delta va Omikronga qarshi vaksinaning uchinchi dozasi samaradorligi to‘g‘risida hisobotni e‘lon qildi [5]. Amerika Tibbiyot Assotsiatsiyasi (JAMA) kuchaytiruvchi dozalarni qabul qilgan shaxslarning natijalari haqida xabar berdi. Ma‘lum bo‘lishicha, vaksinaning uchinchi dozasi Omikron bilan kasallanish xavfini ikki doza vaksina olganlarga nisbatan 66 foizga kamaytirgan.

Vanderbilt universiteti tibbiyot fakulteti professori Uilyam Shaffnerning so‘zlariga ko‘ra, har to‘rt amerikalikdan biri kuchaytiruvchi vaksinaga ega. Ayni paytda AQSHda infeksiyaning 99% holatlari Omikron shtammiga bog‘liq, shuning uchun vaksinaning 3-dozasini qabul qilish muhimdir. Shu bilan birga, aholining 20 foizi hali emlanmagan.



Eslatib o‘tamiz, birinchi hisobotda Qo‘shma Shtatlar (CDC) koronavirusga qarshi vaksinaning emlanmagan odamlarga nisbatan samaradorligi haqida xabar bergan edi. Ikkinchi hisobotda Delta bilan solishtirganda Omicronga qarshi vaksina samaradorligi haqida dalillar mavjud.



Yaponiyada Rossiyaning “Sputnik V” vaksinasining klinikoldi sinovlari o‘tkaziladi

Yaponiyaning “Hibiya Kokusai Clinic” tibbiyot muassasasi “Rossiya adenovirus vaktsinalarining afzalliklari va xalqaro tibbiyot hamjamiyatidagi obro‘cini tan olish” [6] ni ta’kidlab, Rossiyaning “Sputnik V” va “Sputnik Light” vaktsinalarini klinikoldi sinovlar loyahasini rasman taqdim etdi.



«Hibiya Kokusai klinikasi rahbariyati vakillari K. Kosaka va A. Suzuki o‘z chiqishlarida Rossiya adenovirus vaktsinalarining afzalliklari va ularning xalqaro tibbiyot hamjamiyatidagi obro‘-e’tiborini e’tirof etishiga e’tibor qaratdilar, bu ko‘plab tadqiqotlar va nashrlar, jumladan, taniqli tibbiyot fanlari tomonidan tasdiqlangan deb xabar berdi The Lancet ixtisoslashtirilgan jurnali.

Kompaniya vakillari, shuningdek, shifokorlar tomonidan samaradorligini tasdiqlash uchun bemorlarning iltimosiga binoan Rossiya preparatlari bilan emlash sinovlar doirasida amalga oshirilishini ta’kidladilar [7]. Hamkorlik doirasida “Sputnik V” va “Sputnik Light” bo‘yicha tayyorgarliklar Yaponiyada sertifikatlanishi kutilmoqda.



Olimlar, shuningdek, emlashdan keyin COVID-19 ga antitanalarning ortishi, bu antitanalar inson organizmida qancha vaqt saqlanishini, shuningdek, ularning samaradorligi va vaktsinalarning xavfsizligini tekshirishini rejalashtirmoqda [8].

Rossiyada koronavirusning turli shtammlariga qarshi vaksinalar ishlab chiqila boshlandi

Rossiyaning Biocad biotexnologiya kompaniyasi turli shtammlar uchun koronavirusga qarshi vaksinaning monovalent (virusning bir shtammiga qarshi) versiyalarini tayyorlamoqda. Bu haqda kompaniya bosh direktori Dmitriy Morozov ma'lum qildi. Vaksinalar ketma-ket qo'llanilishi kerak. Ularning samaradorligi klinik tadqiqotlar bilan aniqlanishi kerak [9].

“Biz turli shtammlar uchun monovalent variantlarni tayyorlamoqdamiz va vaksinalarini izchil qo'llashni boshlaymiz, ammo faqat klinik tadqiqotlar qaysi sxema samaradorli ekanligini ko'rsatadi”, dedi Morozov.

Uning ta'kidlashicha, Biocad tomonidan ishlab chiqilgan BCD-250 koronavirus vaktsinasi klinik sinovlar bosqichidan avval va ular tugagunga qadar uning COVID-19 shtammlariga samaradorligi haqida gapirishga hali erta. Uning so'zlariga ko'ra, kompaniyaning birinchi ustuvor yo'nalishi joriy vaktsina variantining samaradorligi va xavfsizligini sinab ko'rishdir.

“Hozirda assambleyaning birinchi versiyasining klinik tadqiqotlari olib borilmoqda.

Agar tadqiqotlar muvaffaqiyatli yakunlansa, vaktsinani yangi shtammlarga moslashtirish vazifasi osonlik bilan amalga oshiriladi, chunki vaktsina adeno-assotsiatsiyalangan viruslar platformasida ishlab chiqilgan. Laboratoriyalarda turli mashhur shtammlar uchun moslashish variantlari to'plangan, biroq birinchi navbatda klinik sinovlarning tugashini kutish kerak”, deb tushuntirdi Morozov.



Avvalroq, Biocad COVID-19 ga qarshi vaktsina uchun patent olgan. Vaktsina 5-turdagi adenovirusga asoslangan vektor hisoblanadi. U kiritilgandan so'ng, inson tanasi kodon bilan optimallashtirilgan nuklein kislotadan foydalanish orqali SARS-CoV-2 virusiga o'ziga xos immunitetni rivojlantiradi. Vaktsina koronavirus

infeksiyasining oldini olish uchun ham ishlatilishi mumkin. Preparatning klinik sinovlari 2021-yilning kuzida boshlangan [10].

Ukrainada COVID-19 ga qarshi “kuchaytiruvchi” dozalarni olishning minimal muddati 2 barobarga qisqartirildi


Ukraina Vazirlar Mahkamasi COVID-19 vaksinasining kuchaytiruvchi dozasi olish uchun emlash bosqichlari orasidagi minimal muddat - 90 kuni belgiladi [11].

Bundan tashqari, Vazirlar Mahkamasi tomonidan COVID-19 vaksinasining kuchaytiruvchi dozasi olishning maksimal muddati – 270 kun etib belgilandi. Ta’kidlanishicha, bu muddat bitta vakcina bilan emlash uchun ham, aralash emlash sxemalaridan foydalanganda ham qo’llaniladi.



Bundan tashqari, farmonda kuchaytiruvchi doza kiritilgandan keyin COVID-sertifikatini olishda “Qabul qilinganlar soni, shuningdek seriyadagi dozalar soni” ustuniga “(booster/booster)” belgisi qo’yilishi nazarda tutilgan [12].

1. Reported Cases and Deaths by Country, Territory, or Conveyance // <https://www.worldometers.info/coronavirus/> (30.01.2022)
2. Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (30.01.2022)
3. COVID-19 Vaccine Market Dashboard // <https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> (30.01.2022)
4. Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html> (30.01.2022)
5. Moderna планирует запустить единую вакцину против Covid и гриппа // <https://sud.ua/ru/news/abroad/227389-moderna-planiruet-zapustit-edinuyu-vaktsinu-protiv-covid-i-grippa> (30.01.2022)
6. Moderna aims to launch single Covid and flu booster jab within two years // <https://www.theguardian.com/business/2022/jan/17/moderna-aims-to-launch-single-covid-and-flu-booster-jab-within-two-years> (30.01.2022)
7. Ученые из Цюриха научились предсказывать, у кого больше всего шансов заболеть длительным COVID-19 // <https://novostivl.ru/post/246986/> (30.01.2022)
8. Ученые научились предсказывать, у кого больше всего шансов заболеть длительным COVID-19 // <https://hightech.fm/2022/01/26/predict-diagnose> (30.01.2022)
9. Иммунная полузащита // https://www.kommersant.ru/doc/5182130?from=top_main_2 (30.01.2022)
10. Белорусскую вакцину от COVID-19 сравнили по выработке антител с мировыми аналогами // <https://www.belnovosti.by/koronavirus-covid-19/beloruskuyu-vakcinu-ot-covid-19-sravnili-po-vyrabotke-antitel-s-mirovymi> (30.01.2022)
11. Белорусская вакцина от COVID-19 не вызывает побочных явлений – Гусаков // <https://sputnik.by/20220126/beloruskaya-vaktsina-ot-covid-19-ne-vyzyvaet-pobochnykh-yavleniy--gusakov-1059781606.html> (30.01.2022)
12. Белорусская вакцина от коронавируса не вызывает побочных явлений – Гусаков // <https://politring.com/country/51064-beloruskaya-vakcina-ot-koronavirusa-ne-vyzyvaet-pobochnykh-yavleniy-gusakov.html> (30.01.2022)
13. Гусаков: Белорусская вакцина стимулирует выработку антител против COVID-19 не ниже мировых аналогов // <http://zviazda.by/ru/news/20220126/1643178171-gusakov-beloruskaya-vakcina-stimuliruet-vyrabotku-antitel-protiv-covid-19> (30.01.2022)



O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi
Ilmiy-texnik axborot markazi

Toshkent-2022